230 related articles for article (PubMed ID: 36283150)
1. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.
Darcy S; Alexander M; McCarthy A; O'Dowd S
J Neurovirol; 2022 Feb; 28(1):145-150. PubMed ID: 34874539
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
8. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
[TBL] [Abstract][Full Text] [Related]
10. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
11. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.
Haghikia A; Perrech M; Pula B; Ruhrmann S; Potthoff A; Brockmeyer NH; Goelz S; Wiendl H; Lindå H; Ziemssen T; Baranzini SE; Käll TB; Bengel D; Olsson T; Gold R; Chan A
PLoS One; 2011 Apr; 6(4):e18506. PubMed ID: 21533133
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
14. Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.
Bohra C; Sokol L; Dalia S
Cancer Control; 2017; 24(4):1073274817729901. PubMed ID: 28975841
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.
Berger JR; Houff S
Neurol Res; 2006 Apr; 28(3):299-305. PubMed ID: 16687057
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.
Williamson EML; Berger JR
Neurotherapeutics; 2017 Oct; 14(4):961-973. PubMed ID: 28913726
[TBL] [Abstract][Full Text] [Related]
17. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
18. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.
Focosi D; Tuccori M; Maggi F
Rev Med Virol; 2019 Nov; 29(6):e2077. PubMed ID: 31369199
[TBL] [Abstract][Full Text] [Related]
20. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
